Full View

Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation

YH Chan, CT Kuo, YH Yeh, SH Chang, LS Wu… - Journal of the American …, 2016 - jacc.org
Background: It is unclear whether the non–vitamin K antagonist oral anticoagulant agents
rivaroxaban and dabigatran are superior to warfarin for efficacy and safety outcomes in …
被引用次数：173 相关文章
[PDF] medtrib.cn

[PDF][PDF] Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation

YH Chan, CT Kuo, YH Yeh, SH Chang… - JOURNAL OF THE …, 2016 - file.medtrib.cn
Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With
Nonvalvular Atrial Fibrillation Page 1 Thromboembolic, Bleeding, and Mortality Risks of …

Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation

YH Chan, CT Kuo, YH Yeh… - Journal of the …, 2016 - pubmed.ncbi.nlm.nih.gov
Background It is unclear whether the non-vitamin K antagonist oral anticoagulant agents
rivaroxaban and dabigatran are superior to warfarin for efficacy and safety outcomes in …
[HTML] sciencedirect.com

[HTML][HTML] Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation

YH Chan, CT Kuo, YH Yeh, SH Chang, LS Wu… - Journal of the American …, 2016 - Elsevier
Background It is unclear whether the non–vitamin K antagonist oral anticoagulant agents
rivaroxaban and dabigatran are superior to warfarin for efficacy and safety outcomes in …

[引用][C] Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation

YH Chan, CT Kuo, YH Yeh, SH Chang, LS Wu… - Journal of the American …, 2016 - cir.nii.ac.jp
Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians
With Nonvalvular Atrial Fibrillation | CiNii Research CiNii 国立情報学研究所 学術情報 …

Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation.

YH Chan, CT Kuo, YH Yeh, SH Chang… - Journal of the …, 2016 - europepmc.org
Background It is unclear whether the non-vitamin K antagonist oral anticoagulant agents
rivaroxaban and dabigatran are superior to warfarin for efficacy and safety outcomes in …

Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation

YH Chan, CT Kuo, YH Yeh, SH Chang, LS Wu… - Journal of the American …, 2016 - infona.pl
It is unclear whether the non–vitamin K antagonist oral anticoagulant agents rivaroxaban
and dabigatran are superior to warfarin for efficacy and safety outcomes in Asians with …
[PDF] core.ac.uk

[PDF][PDF] Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation

YH Chan, CT Kuo, YH Yeh, SH Chang, LS Wu… - JOURNAL OF THE …, 2016 - core.ac.uk
Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians
With Nonvalvular Atrial Page 1 Thromboembolic, Bleeding, and Mortality Risks of …
[PDF] medtrib.cn

[PDF][PDF] Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation

YH Chan, CT Kuo, YH Yeh, SH Chang… - JOURNAL OF THE …, 2016 - file.medtrib.cn
Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With
Nonvalvular Atrial Fibrillation Page 1 Thromboembolic, Bleeding, and Mortality Risks of …

[引用][C] Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation

YH Chan, CT Kuo, YH Yeh, SH Chang… - Journal of the …, 2016 - Elsevier Limited